Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-04-26

Clinical Trial Update: A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and efficacy of secukinumab in Giant Cell Arteritis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Giant Cell Arteritis | Phase 2 | Status: COMPLETED | Results posted: 2023-04-26